Targeting AXL cellular networks in kidney fibrosis

Sturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens · 2024

Read Targeting AXL cellular networks in kidney fibrosis by Sturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11570270.txt.

Description

Chronic kidney disease often ends in fibrosis, scar tissue that strangles the organ, and a receptor called AXL sits near the center of that process. Sturla Grøndal and six co-authors test blocking it in mice whose urinary tract was tied off on one side, a standard fibrosis model. The animals received an AXL-blocking drug from the start, and their kidneys were profiled cell by cell at early and late stages.

The drug reduced fibrosis. Protected kidneys held fewer scar-driving vessel cells, kept more of their lining cells, and drew in fewer immune cells. Mapping showed AXL concentrated in a network of interacting cell types, from vessel support cells to immune sentinels. The authors propose that fibrosis advances through that network, and that medicines aimed at AXL deserve trials in kidney patients.

Catalog record

CREATORSturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11570270

Browse the full library · About the Tower of Babel